A team led by Michael Trauner at MedUni Vienna's Division of Gastroenterology and Hepatology demonstrated the beneficial effect of synthetically produced bile acid with the active agent nor-ursodeoxycholic acid (nor-urso) in the hitherto incurable liver disease primary sclerosing cholangitis (PSC) around two years ago.
Read More
>>Hollywood's Exotic Secret For Healthy Weight Loss
0 Response to "Trial shows nor-urso as an effective treatment option for nonalcoholic fatty liver disease"
Post a Comment